FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer

FOLFIRI or mFOLFOX6 as Adjuvant Chemotherapy Regiment After Neo-adjuvant Chemotherapy With FOLFIRI in Patients With Advanced Colorectal Cancer: a Randomized, Multicenter Clinical Trial

the aim of this study is to observe the effect of irinotecan-based regimen in patients with advanced colorectal cancer.

Inclusion Criteria:

• histologically confirmed adenocarcinoma in colorectal cancer
• clinical stage Ⅲ or Ⅳa(with potential radical resective metastatic lesions),≥ 12 lymph nodes examined
• no cancer cells were found in ascites
• Eastern Cooperative Oncology Group(ECOG) performance status of 0-2
• male or female, between 18 and 75 years old
• adequate hematologic, hepatic and renal functions
• without severe heart disease in the last 6 months before enrolled. If with hypertension or coronary artery disease, it can be controlled
• not enrolled into others clinical trial during this study
• all patients should sign the informed consent

Exclusion Criteria:

• can not be tolerated operation
• receiving others therapy(including Traditional Chinese herbs)for this disease, can not obey the investigator during the study
• can not be tolerated the adverse effect of drugs in these regimens
• major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from major surgery
• metastatic disease more than one organ
• pregnant or lactating women